Results 171 to 180 of about 306,427 (235)

Mavacamten in Obstructive Hypertrophic Cardiomyopathy: National Insights on Access and Safety Profile From Real-World Data. [PDF]

J Am Heart Assoc
Fath AR, Aglan A, Naidu SS, Mader MJ, Chilton RJ, Elgendy IY, Maron MS, Rowin EJ.   +7 more
europepmc   +1 more source

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.

JAMA Cardiol
Lewis GD, Garcia-Pavia P, Masri A, Merkely B, Nassif ME, Peña-Peña ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, de Barros Correia E, Dybro AM, Kulac IJ, Lakdawala NK, Mann A, Maron MS, McGinnis S, Nair A, Newlands C, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Elliott PM, MAPLE-HCM Investigators.   +34 more
europepmc   +1 more source

Therapeutic Sequencing in Obstructive Hypertrophic Cardiomyopathy: Seeing the Forest Through the Trees. [PDF]

JACC Heart Fail
Reza N.
europepmc   +1 more source

Access Challenges for Septal Reduction Therapy Among Individuals With Obstructive Hypertrophic Cardiomyopathy. [PDF]

J Am Heart Assoc
Owens AT, Schuler P, Jiang J, Han X, Hernandez EM, Anderson A, Fang Y, Steffens A, Dubey A.   +8 more
europepmc   +1 more source

Hypertrophic Obstructive Cardiomyopathy

Journal of Interventional Cardiology, 1996
openaire   +1 more source

Transapical Edge-to-Edge Repair for Systolic Anterior Motion in Obstructive Hypertrophic Cardiomyopathy. [PDF]

JACC Case Rep
Song Y, Yan Y, Li YX, Ruan LT, Jiang Y, Chen Q, Guo FW, Dong YL, Wang F.   +8 more
europepmc   +1 more source

Percutaneous endomyocardial ablation as a septal reduction strategy in symptomatic obstructive hypertrophic cardiomyopathy: A 20-year single-center observational experience. [PDF]

HeartRhythm Case Rep
Casey A, McCormick J, Keane D.
europepmc   +1 more source

Anesthetic management of transapical beating-heart septal myectomy in a child with obstructive hypertrophic cardiomyopathy: a case report. [PDF]

BMC Anesthesiol
Yu H, Cheng L, Zheng H.
europepmc   +1 more source

Cardiogenic shock and atrial fibrillation after mavacamten dose escalation in obstructive hypertrophic cardiomyopathy: a case report. [PDF]

Eur Heart J Case Rep
Jeong WJ, Kim SE, Cho SW, Namgung J, Ko KY.   +4 more
europepmc   +1 more source

OPTEM-oHCM: OPtimal Targeted Polymer-based EMbolization for Obstructive Hypertrophic CardioMyopathy. [PDF]

JACC Case Rep
Martins Filho E, Schumann Munhoz T, Munhoz Júnior S.   +2 more
europepmc   +1 more source